Therefore, in this study, the expression and prognostic impact of RBM3 was examined in a consecutive cohort of radiotherapy- and chemotherapy-naive adenocarcinoma of the esophagus and stomach (n = 173). Here, RBM3 is linked to adenocarcinoma.